Abstract
Historically, antihyperglycemics for patients with Type 2 diabetes have not been managed by cardiology clinicians. This paradigm has shifted after the release of cardiovascular (CV) outcome trials using 2 new classes of antihyperglycemics agents, sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide 1 receptor agonists, which demonstrated a decrease in all-cause mortality, CV death, and stroke. The purpose of this pilot program was to translate this trial data into practice by developing a protocol for cardiology-based nurse practitioners (NPs) to initiate these agents. Cardiology NPs demonstrated the feasibility of initiating these agents within a cardiology practice using a shared decision-making, patient-centric framework.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
